Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other neoplasm 1

Conditions

Lymphoma 2Waldenstrom Macroglobulinemia 1Precancerous Conditions 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Melphalan 20Cyclophosphamide 17Dexamethasone 14Peripheral Blood Stem Cell Transplantation 12Filgrastim 9sargramostim 8fludarabine phosphate 7Interferon-alpha 7Busulfan 7Bortezomib 7Vincristine 6Thalidomide 6Prednisone 6Doxorubicin 5Antilymphocyte Serum 5Radiotherapy 4Cyclosporine 4Mycophenolic Acid 3Methylprednisolone 3Idarubicin 3Etoposide 3Drug Therapy 3Ascorbic Acid 3Arsenic Trioxide 3Rituximab 2Methotrexate 2Interleukin-12 Subunit p35 2Ifosfamide 2Cytarabine 2Carmustine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neoplasms, Plasma Cell × alethine × Clear all
NCT00006466 2013-12-18

Beta Alethine in Treating Patients With Myeloma

National Cancer Institute (NCI)

Phase 1/2 Unknown
Other neoplasmPlasma cell

Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡